Delta-Fly Pharma (TSE:4598) ROCE %: -794.86% (As of Mar. 2026)


TSE:4598 Delta-Fly Pharma Inc TSE:4598
30 GF Score
Price 円135.00
! 2 Warning Signs
View Full Analysis

What is Delta-Fly Pharma ROCE %?

Delta-Fly Pharma TSE:4598 +2.27% 30 ROCE % is -794.86% as of Mar. 2026. GuruFocus rates TSE:4598 with a GF Score™ of 30/100. The stock has 2 warning signs investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Delta-Fly Pharma's annualized ROCE % for the quarter that ended in Mar. 2026 was -794.86%.

Delta-Fly Pharma  (TSE:4598) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Delta-Fly Pharma ROCE % Related Terms

Delta-Fly Pharma ROCE % Historical Data

* Premium members only.

The historical data trend for Delta-Fly Pharma's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Delta-Fly Pharma ROCE % Chart

Delta-Fly Pharma Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
ROCE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -58.06 -130.00 -138.69 -226.19 -1,029.64

Delta-Fly Pharma Semi-Annual Data
Mar17 Mar18 Sep18 Mar19 Sep19 Mar20 Sep20 Mar21 Sep21 Mar22 Sep22 Mar23 Sep23 Mar24 Sep24 Mar25 Sep25 Mar26
ROCE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -198.11 -236.75 -533.90 -525.04 -794.86
TSE:4598
30GF Score
Delta-Fly Pharma Inc TSE:4598
ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Delta-Fly Pharma ROCE % Calculation

Delta-Fly Pharma's annualized ROCE % for the fiscal year that ended in Mar. 2026 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Mar. 2026 )  (A: Mar. 2025 )(A: Mar. 2026 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Mar. 2026 )  (A: Mar. 2025 )(A: Mar. 2026 )
=-1605.088/( ( (434.334 - 156.538) + (246.67 - 212.69) )/ 2 )
=-1605.088/( (277.796+33.98)/ 2 )
=-1605.088/155.888
=-1,029.64 %

Delta-Fly Pharma's ROCE % of for the quarter that ended in Mar. 2026 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Mar. 2026 )  (Q: Sep. 2025 )(Q: Mar. 2026 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Mar. 2026 )  (Q: Sep. 2025 )(Q: Mar. 2026 )
=-1547.746/( ( (508.653 - 153.195) + (246.67 - 212.69) )/ 2 )
=-1547.746/( ( 355.458 + 33.98 )/ 2 )
=-1547.746/194.719
=-794.86 %

(1) Note: The EBIT data used here is two times the semi-annual (Mar. 2026) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROCE % →
What does a ROCE % of -794.86% mean?
Delta-Fly Pharma (TSE:4598) has a ROCE % of -794.86% as of Mar. 2026.
Is Delta-Fly Pharma's ROCE % too high?
Delta-Fly Pharma's current ROCE % is -794.86%. Overall, Delta-Fly Pharma has a GF Score™ of 30/100, reflecting its overall financial health beyond just this single metric.
How does Delta-Fly Pharma's ROCE % compare to VRTX and REGN?
Delta-Fly Pharma's ROCE % of -794.86% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROCE % for a Biotechnology company?
A good ROCE % depends on the Biotechnology industry context. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROCE % mean?
A high ROCE % can signal that a stock is expensive relative to its fundamentals. Delta-Fly Pharma's current ROCE % is -794.86%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Delta-Fly Pharma stock overvalued right now?
Delta-Fly Pharma (TSE:4598) has a current ROCE % of -794.86%. The current ROCE % is -794.86%. Delta-Fly Pharma's overall GF Score™ is 30/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROCE % calculated?
ROCE % is calculated from a company's financial statements. For Delta-Fly Pharma (TSE:4598), the current ROCE % is -794.86% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Delta-Fly Pharma Business Description

Address 37-5, Miyajima Nishikino, Kawauchi-cho, Tokushima, JPN, 771-0116
Delta-Fly Pharma Inc is a Japan-based company mainly engaged in the discovery and development of gentle anti-cancer agents with module technology.
30GF Score

Get the complete analysis for TSE:4598

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

円135.00
Price